Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors

Abstract

PURPOSE: Although EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have shown dramatic effects against EGFR mutant lung cancer, patients ultimately develop resistance by multiple mechanisms. We therefore assessed the ability of combined treatment with the Met inhibitor crizotinib and new generation EGFR-TKIs to overcome resistance to first-generation EGFR-TKIs. EXPERIMENTAL DESIGN: Lung cancer cell lines made resistant to EGFR-TKIs by the gatekeeper EGFR-T790M mutation, Met amplification, and HGF overexpression and mice with tumors induced by these cells were treated with crizotinib and a ne

Abstract by Shigeki Nanjo; Tadaaki Yamada; Hiroshi Nishihara; Shinji Takeuchi; Takako Sano; Takayuki Nakagawa; Daisuke Ishikawa; Lu Zhao, PLoS ONE (2013) — licensed CC BY 4.0.

Related failures